Clinical trials: AD - Alzheimer's Disease
Alzheimer Disease
Finding Retinal Biomarkers in Alzheimer's Disease
CSF Alzheimer's disease (AD) biomarkers are the only one that reflect both Aβ and tau pathologies. There is increasing evidence for the presence of AD abnormalities in the retina of AD patients.
- Trial name
- FIREBALZ (NCT05067010)
- Testing
- Detailed ophthalmologic examination
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimers Disease
A Postmarketing Study of LEQEMBI in United Kingdom (UK) Participants With Alzheimer's Disease (AD)
The primary purpose of the study is to describe the incidence and severity of known adverse events (AEs), including Amyloid-Related Imaging Abnormalities Oedema/Effusion (ARIA-E), Amyloid-Related Imaging…
- Trial name
- NCT07781345
- Testing
- No Intervention
- Where
- 3 sites in United Kingdom
- Volunteers
- 400 people
- Sponsor
- Eisai Limited
Alzheimer Disease
Memesto Wearable Device for Persons With Dementia
An estimated 70% of the 7.2+ million people in the U.S. with Alzheimer's Disease and Alzheimer's Disease-Related Dementias experience agitation, characterized by poorly organized and purposeless psychomotor activity that…
- Trial name
- NCT05153161
- Testing
- Memesto
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Edgewater Safety Systems, Inc.
Dementia, Alzheimer's Disease
Collaboration Between Department of Old Age Psychiatry and Nursing Homes
Dementia is a serious health problem showing an increasing prevalence rate with increasing age. In Norway, about 80% of nursing home patients have dementia. The mean age of nursing home residents in Norway is around 84 years.
- Conditions
- Dementia, Alzheimer's Disease, Behavioral Symptoms, Agitation
- Trial name
- SAM-AKS (NCT01217541)
- Testing
- Education and Supervision, Control
- Where
- Norway
- Volunteers
- 700 people
- Sponsor
- Sykehuset Innlandet HF
Mild Cognitive Impairment
Shanghai Mild Cognitive Impairment Cohort Study
This study was planned 1) to identify individuals with Mild Cognitive Impairment (MCI) who convert to Alzheimer's Disease (AD), and 2) to explore factors associated with the conversion.
- Trial name
- NCT01552265
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Alzheimer's Disease
The Feasibility of Florbetapir Quantitation in Europe
This study will evaluate whether the addition of quantitation as an adjunct to visual interpretations significantly improves the accuracy of Amyvid scan interpretation.
- Trial name
- NCT02107599
- Testing
- Florbetapir (18F)
- Where
- Netherlands
- Volunteers
- 96 people
- Sponsor
- Avid Radiopharmaceuticals
Alzheimer Disease
Levetiracetam for Alzheimer's Disease Neuropsychiatric Symptoms Related to Epilepsy Trial (LAPSE)
Patients with Alzheimer's disease (AD) are increasingly recognized to have seizures in addition to cognitive decline. Seizures may contribute to memory problems as well as other symptoms common in AD like agitation, depression…
- Trial name
- LAPSE (NCT04004702)
- Testing
- Levetiracetam
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Walter Reed National Military Medical Center
Alzheimer Disease, Dementia
Detecting Probable Alzheimer's Disease From Speech Using Linguistical Analysis
The object of this study is to investigate the use of linguistic deficits from speech samples for the early detection of Mild Cognitive Impairment and probable Alzheimer's disease.
- Trial name
- NCT04041895
- Testing
- Audio speech recording
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- East Tennessee State University
Alzheimer Disease, Early Onset, Lewy Body Disease
Patients With Alzheimer's Disease or Related Youth Disease
This study aims to determine factors related to diagnosis delay for patients with young onset dementia (first symptoms before 60 years old) who live in North of France.
- Conditions
- Alzheimer Disease, Early Onset, Lewy Body Disease, Frontotemporal Lobar Degeneration
- Trial name
- PARMAAJJ (NCT03508024)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Lille
Alzheimer Disease
Reported Time Between Onset and Diagnosis of Alzheimer's Disease: Correlation With Objective Parameters
The early diagnosis of Alzheimer's disease is essential to enable patients to have access to the available treatments. However, there is a delay between the diagnosis and the onset of symptoms, which can range from 1 year to more…
- Trial name
- NCT03408041
- Testing
- Medical file data extraction
- Where
- Belgium
- Volunteers
- 129 people
- Sponsor
- Murielle Surquin
Mild Cognitive Impairment, Alzheimer's Disease
Investigating the Clinical Consequences of Flutemetamol-PET-scanning
The study examines subjects where there might be an indication for Amyloid-PET according to the Criteria defined by the Amyloid Imaging Task Force.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Dementia
- Trial name
- NCT02353949
- Testing
- Flutemetamol (Vizamyl)
- Where
- Switzerland
- Volunteers
- 11 people
- Sponsor
- University of Zurich
Alzheimer Disease or Associated Disorder
Coordinated Emergency Department Transitions
The goal of this observational study is to learn the feasibility, acceptability, appropriateness, and adherence to a case management intervention.
- Trial name
- NCT06933849
- Testing
- Structured case management
- Where
- United States
- Volunteers
- 1,376 people
- Sponsor
- Brown University
Alzheimer Disease, Mild Cognitive Impairment
Transcranial Magnetic Stimulation in Mild Cognitive Impairment and Alzheimer Disease
The investigators reviewed 12 years of clinical use in an outpatient neurology setting of transcranial magnetic stimulation (TMS) in patients with Alzheimer's disease (AD) and mild cognitive impairment (MCI) to evaluate safety…
- Trial name
- NCT04771845
- Testing
- Transcranial Magnetic Stimulation
- Volunteers
- 73 people
- Sponsor
- The New York Memory Services
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Dementia
Music & MEmory: A Pragmatic TRial for Nursing Home Residents With ALzheimer's Disease (METRIcAL)_part2
The purpose of this trial is to test the effects of a personalized music intervention (Music and Memory, Inc.) on agitated and aggressive behaviors for nursing home residents with dementia.
- Trial name
- METRIcAL (NCT04850807)
- Testing
- Music & Memory
- Where
- 4 sites in United States
- Volunteers
- 990 people
- Sponsor
- Brown University
Down Syndrome (DS)
Normalization of dyrk1A and APP Function as an Approach to Improve Cognitive Performance and Decelerate AD Progression in DS Subjects: Epigallocatechin Gallate as Therapeutic Tool
Epigallocatechin-3-gallate (EGCG), the major catechin in green tea, is postulated to modulate dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) and amyloid beta precursor protein (APP) gene overexpression in…
- Trial name
- NCT01699711
- Testing
- Epigallocatechin-3-gallate (EGCG)
- Where
- Spain
- Volunteers
- 87 people
- Sponsor
- Parc de Salut Mar
Alzheimer's Disease
Post-marketing Surveillance of Donepezil Hydrochloride -Investigation of the Factors That Affect Aricept Medication Persistence Rate and the Safety and Efficacy in Patients With Alzheimer's Disease in Clinical Practice
To investigate the factors that affect Aricept medication persistence rate and the safety and efficacy in patients with Alzheimer's Disease in clinical practice
- Trial name
- NCT02162264
- Testing
- Donepezil Hydrochloride
- Where
- Japan
- Volunteers
- 8,662 people
- Sponsor
- Eisai Co., Ltd.
Diabetes, Alzheimer Disease
The Diabetes Prevention Program Outcomes Study AD/ADRD Project
The DPPOS AD/ADRD project will address the overarching question: What are the determinants and the nature of cognitive impairment among persons with pre-diabetes (PreD) and type 2 diabetes (T2D), who are a high-risk group for…
- Conditions
- Diabetes, Alzheimer Disease, Dementia, Vascular, Dementia
- Trial name
- DPPOS-4 (NCT05704309)
- Where
- 27 sites in United States
- Volunteers
- 1,976 people, healthy volunteers welcome
- Sponsor
- Marinella Temprosa
Alzheimer Disease, Dementia Alzheimers
Optical Coherence Tomography in Cerebral Amyloidosis
In this observational study, the investigators aim to evaluate whether changes in the retinal and choroidal circulation, as assessed by Optical Coherence Tomography (OCT) and the quantification of retinal amyloid deposits using…
- Conditions
- Alzheimer Disease, Dementia Alzheimers, Dementia, Lewy Body Disease
- Trial name
- NCT03472482
- Testing
- non-invasive retinal imaging
- Where
- Belgium
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Alzheimer's Disease
AAB-001 (Bapineuzumab) Open-Label, Long-Term Extension Study in Patients With Mild to Moderate Alzheimer's Disease
This is a multicenter, open-label, long-term extension study in male and female patients with mild to moderate Alzheimer's Disease (AD) who must have completed one of the following studies: AAB-001-201 or AAB-001-102.
- Trial name
- NCT00606476
- Testing
- Bapineuzumab (AAB-001)
- Where
- 29 sites in United States
- Volunteers
- 194 people
- Sponsor
- JANSSEN Alzheimer Immunotherapy Research & Development, LLC